Zobrazeno 1 - 10
of 145
pro vyhledávání: '"shingrix"'
Autor:
Maxime Hentzien, Fabrice Bonnet, Enos Bernasconi, Emmanuel Biver, Dominique L. Braun, Aline Munting, Karoline Leuzinger, Olivier Leleux, Stefano Musardo, Virginie Prendki, Patrick Schmid, Cornelia Staehelin, Marcel Stoeckle, Carla S. Walti, Linda Wittkop, Victor Appay, Arnaud M. Didierlaurent, Alexandra Calmy
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The burden of herpes zoster (shingles) virus and associated complications, such as post-herpetic neuralgia, is higher in older adults and has a significant impact on quality of life. The incidence of herpes zoster and post-herpeti
Externí odkaz:
https://doaj.org/article/3f8091d417ad43dbb2cb4768c4041a15
Autor:
Lulu Huang, Tongyi Zhao, Weijun Zhao, Andong Shao, Huajun Zhao, Wenxuan Ma, Yingfei Gong, Xianhuan Zeng, Changzhen Weng, Lingling Bu, Zhenhua Di, Shiyu Sun, Qinsheng Dai, Minhui Sun, Limei Wang, Zhenguang Liu, Leilei Shi, Jiesen Hu, Shentong Fang, Cheng Zhang, Jian Zhang, Guan Wang, Karin Loré, Yong Yang, Ang Lin
Publikováno v:
Emerging Microbes and Infections, Vol 13, Iss 1 (2024)
ABSTRACTHerpes zoster remains an important global health issue and mainly occurs in aged and immunocompromised individuals with an early exposure history to Varicella Zoster Virus (VZV). Although the licensed vaccine Shingrix has remarkably high effi
Externí odkaz:
https://doaj.org/article/10860985a51042b89c1e33835ed869db
Autor:
Francesco De Caro, Francesca Malatesta, Nadia Pecoraro, Mario Capunzo, Luna Carpinelli, Simona Caruccio, Giuseppina Cersosimo, Maria Costantino, Claudio Giordano, Walter Longanella, Vincenzo Patella, Arcangelo Saggese Tozzi, Giulia Savarese, Pio Sinopoli, Emilia Anna Vozzella, Giuseppina Moccia
Publikováno v:
Vaccines, Vol 12, Iss 4, p 442 (2024)
Background: A nudge intervention against Herpes Zoster, created and implemented in Italy, is presented in order to administer the Shingrix vaccine on a sample of frail patients, as required by the National Prevention Plan. Individual and contextual f
Externí odkaz:
https://doaj.org/article/c487787be7524cc1b9d7ec0630179c21
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 2, Pp 711-726 (2023)
Abstract Introduction Zostavax, the live-attenuated vaccine used to prevent herpes zoster (HZ), has been available to individuals aged 70 and 71–79 years (phased catch-up) via Australia’s National Immunisation Program (NIP) since 2016. There are
Externí odkaz:
https://doaj.org/article/9f6fa91bae3a4ff9bb9e1f2874babd0e
Publikováno v:
Reports, Vol 7, Iss 1, p 5 (2024)
We present a case of serious and progressive neuropathy shortly following the administration of the herpes zoster subunit (HZ/su) vaccine, otherwise known as Shingrix. The progressive neuropathy occurred a week following the vaccination and progresse
Externí odkaz:
https://doaj.org/article/67a66dd4415b4c4ebad49e0bb3e2d0ad
Autor:
Tracy J. Lu, Christopher N. Ta
Publikováno v:
Case Reports in Ophthalmology, Vol 13, Iss 1, Pp 104-108 (2022)
We present a case of herpes zoster keratitis reactivation shortly following the Shingrix vaccine. In our patient, reactivation of herpes zoster keratitis occurred a few weeks following the herpes zoster subunit (HZ/su) vaccine. The development of her
Externí odkaz:
https://doaj.org/article/c1c69d91405843d785ac17603a2e8bca
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 12, Pp 5304-5310 (2021)
Epidemiologic data regarding the risk of Guillain-Barré syndrome (GBS) following herpes zoster (HZ) are limited. We conducted a self-controlled case series analysis using two large national data sources to evaluate the risk of GBS following HZ among
Externí odkaz:
https://doaj.org/article/61a324f1c28d4030a4e086dc1828c4b9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Cara B. Janusz, Tara C. Anderson, Andrew J. Leidner, Grace M. Lee, Kathleen Dooling, Lisa A. Prosser
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
The Advisory Committee on Immunization Practices (ACIP) recommends recombinant zoster vaccine (RZV) to prevent against herpes zoster (HZ) and related complications in immunocompetent adults ≥50 y and immunocompromised adults ≥19 y. In 2019, a sta
Externí odkaz:
https://doaj.org/article/60b984d5b82846baa32aac10192e5504